Favitol 400 Tablet contains Favipiravir 400 mg, a broad-spectrum antiviral agent that selectively inhibits RNA-dependent RNA polymerase, preventing replication of RNA viruses. Its high-dose formulation ensures enhanced antiviral efficacy, making it suitable for management of moderate to severe viral infections.
Clinically, Favitol 400 Tablet is indicated for acute RNA viral infections, including influenza and other emerging RNA virus diseases. The higher dosage is particularly useful in early intervention protocols to reduce viral load, prevent disease progression, and improve recovery time.
The tablet formulation ensures precise dosing, consistent bioavailability, and reliable therapeutic outcomes, supporting use in hospitals, infectious disease clinics, and government antiviral programs. Its oral administration allows for patient-friendly compliance and convenient integration into treatment regimens.
Favitol 400 Tablet also aids in controlling viral replication, reducing transmission risk, and improving clinical prognosis in affected patients. It provides a safe, evidence-based antiviral therapy for healthcare providers seeking effective, high-potency treatment options for RNA viral infections.